Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why if you don't like it and think it has a lot of problems you keep staying here?
This company has a lot of issues and problems.
The next financial report is what I’m most curious about.
You must have bought more. Aren’t you worried about the small PPP loan? You brought that up up? Correct?
Any reason people should care what you are saying?
Lots of end of day buys and probably into the last second of AH.
Usually indicates same day short covers and penny pushers to make the chart green (which is illegal manipulative trading) if the buys are small and recurrent.
No more nice trials? Since no results exist to the public eye..
“FDA no longer needs to require animal tests before human drug trials
New law welcomed by animal welfare groups, but others say change won’t happen fast.”
https://www.science.org/content/article/fda-no-longer-needs-require-animal-tests-human-drug-trials
Yes I agree...at least I'm going out with a good income for the moment it's just speculation
It’d be a good time for SBFM to put out a verifiable PR, or anything that shows forward promise, and not repeating past PR failures or omissions of results, partners, and other abandoned information that was never followed up on.
Today a bit of a climb... The important thing is to be in the green....waiting for a jump...
Yesterday I entered this title that I had been looking at for some time, let's hope for a flare up on some news soon
Investor faith absolutely lost.
CFO should be laid off or fired. What value has he added along with Christine, the new head of the paid IR firm?
Seems to have worked well.
The short being, as long as the share structure doesn’t increase, SBFM will pop like Mt St Helen’s and then fizzle out on no news, updates or anything if there is a big run.
What’s kind of weird is I don’t think any of these stooges, directors, etc can dilute.
The institutions can, but pretty sure SBFM creeps can’t because the SEC denied their requests.
Now these guys are buying up shares and hold almost 50% of the 22M O/S.
That’s kind of interesting….
The bad news is SBFM can increase the A/S and O/S further, as they recently did from 18M to 22M.
They also most likely created a material impact and screwed up with their LNP partner. They didn’t file an 8-K because shareholders might call them and verify they are real.
The answer is Blowin in their pockets.
Why do you think it’s an LNP in Vancouver?
Is this the LNP Company in Vancouver, BC, Canada that SBFM is working with?
https://acuitastx.com
Looks like they are working with Pfizer: https://acuitastx.com/wp-content/uploads/2022/01/Acuitas-Pfizer-Agreement-Release.pdf
Terrible what happened here
Is it for mice? So far, that’s all it’s good for, if it hasn’t been replaced by K1.1. Same with adva-27a and SBFM-PL-4.
FDA won’t approve any of their claims and they’ve been trying since the 2000’s.
SEC denied all their requests and refused to review them any further.
SBFM can’t get a loan according to their latest filing.
Nora had 150K in profit until 3/2022 when they bought a plant and a bunch of employees and doubled their profit or revenue to 350K.
SBFM now has to keep the show running with next to nothing in net profit and tons of employees.
The next financial is due and we’ll see what kind of shape this company is in at that time.
Nora CEO has over 7M shares of the 22M O/S and gets annual increases.
That’s more than Camille, Slilaty and that other guy combined.
More COVID ahead (see article below). SBFM needs to pick up the pace in 2023 to develop their COVID pill!
https://www.cnn.com/2023/01/04/health/public-health-concerned-xbb/index.html
Shorts probably caught off guard. No updates or tweets
Happy 2nd SBFM Trading Day of 2023! Day 1 was definitely a good start to the New Year. Looking forward to some unexpected positive excitement in the coming days/weeks/months!
No he hasn’t …. Stupidest post of THIS year so far….
Working with an insider to what? If hed just focus on running a solid business he wouldn’t have to worry about an opinion board. That is exactly why this company sucks. Worried about shit that isn’t even a problem.
Happy 1st SBFM Trading Day of 2023. Looking for better days, weeks and months ahead!
He’s losing his hair over the pps. Isn’t there a Benzinga PR that Camille is buying up shares like every other week that gets posted to Twitter and ST?
He has to pay Benzinga to do that. It’s part of their PR distribution, to post to social media outlets how great SBFM is and that he is buying shares of his failures in this company as CFO.
You can look at Benzinga and see how he does these things. Guy is not qualified for his so called position.
Interesting rumor, but I'm not sure we have heard the last of the PLpro anti-Coronavirus mice trials from the University of Arizona or the upcoming K1.1-LNP xenograft mice in vivo cancer trials in March 2023.
Nonetheless, the RS has clearly failed. Had the PPS stayed above $4 (or even $2) in 2022 I might have thought otherwise. If it gets back to $2-4+ in 2023 then I'll have different thoughts on this!
Unsubstantiated rumour: Camille has been taking notes and printing out messages of everyone on Reddit, Twitter, Ihub, ST and more and working with an insider because he’s pissed. Really pissed, probably because his mice failed him.
If true I find that to be hilarious because he has only himself and his team to blame.
Welcome back my friend! We are all looking forward to 2023
Pretty much everyone who was all for this company has given up.
Just waiting for the next pump so I can dump. SBFM will never finish any drug.. all we will get is findings are enormous!! Or we are delighted!!!what a joke…new yr but same regurgitated PR..waste of time.. opportunity cost..!!!
Who knows what type of PR will come out, but it will likely be related to progress on the SBFM topics below:
July 2022: expanded collaboration with the University of Arizona to accelerate the development of our novel PLpro inhibitors for our anti-Coronavirus treatment program.
October 2022: acquired Canadian generic pharmaceuticals company, Nora Pharma Inc., with sales of approximately $14 million. Sunshine Biopharma now has over 50 generic prescription drugs on the market in Canada with plans to grow further throughout North America and potentially other markets around the world.
November 2022: vigorously pushed forward with our oncology K1.1 mRNA development program by entering into a key collaboration arrangement with a leading lipid nano-particle (LNP) formulation company in North America. Beginning in March, 2023, our partner generated K1.1-LNP formulations will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer. Should these mice studies prove successful, the Company can advance relatively rapidly to conducting human trials.
2023: objectives going forward will be focused on achieving profitability and investing in our proprietary drug development program.
You think they'll do the same fluff PR 3 Years in a row? That's why your timeframe is implying lol.
Happy to take my last long term losses recently and taking new positions. Looking for the turnaround in 2023.
Our bags may be full of coal now, but 2023 may be the year that SBFM turns it into gold. Check back in 6 months and we'll chat again.
0 trading days left until 2023 and the end of 2022 was not good for SBFM shareholders. Let's see if the management can come into 2023 with a new strategy that rewards vs. punishes existing shareholders.
End of year red close. End of week red close. End of month red close. Since uplist, red close.
year low, on SEC’s radar, received a delisting notice and their partner in crime CytoDyn was busted by the SEC for pumping covid cures.
Good job scammer Slilaty and Camille Shambally. You’re probably next.
I keep seeing FDA Acceptance of IND Application PRs for biopharma companies so perhaps that will be the excitement in 2023 for SBFM. Stock prices seem to go up between 100-300% for those announcements. Time to get the ball rolling!
Below is one example:
https://ih.advfn.com/stock-market/NASDAQ/hoth-therapeutics-HOTH/stock-news/89873816/hoth-therapeutics-announces-fda-acceptance-of-ind
2 more trading days until SBFM starts a new year of trading in 2023! Looking forward to some new found excitement and momentum throughout the new year.
Sunshine Biopharma Inc. (SBFM) Key Ratios
PROFITABILITY
EBIT Margin -512.5%
EBITDA Margin -510.5%
VALUATION MEASURES
PE Ratio 1.00
Enterprise Value $ 14,861,350
Price to Sales 29.4744
Price to Free Cash -4.50
PE High Last 5 Years -0.80
Price To Book 0.40
Price To Cash Flow 0.00
PE Low Last 5 Years -1.00
Price to Tangible Book 0.40
MANAGEMENT EFFECTIVENESS
Receivables Turnover 320.10
Invoice Turnover 1.50
Assets Turnover 0.00
Return Assets -11.83
Return on Equity -13.12
Return on Capital -12.86
INCOME STATEMENTS
Revenue $ 490,878
Revenue Per Share $ 0.0217
7 Day Price Change $ -0.0589
7 Day Percent Change -8.42%
21 Day Price Change $ -0.0784
21 Day Percent Change -10.9%
30 Day Price Change $ -0.1594
30 Day Percent Change -19.93%
Month to Date Price Change $ -0.1505
Month to Date Percent Change -19.02%
Quarter to Date Price Change $ -0.1319
Quarter to Date Percent Change -17.07%
180 Day Price Change $ -0.6194
180 Day Percent Change -49.16%
200 Day Price Change $ -0.6094
200 Day Percent Change -48.75%
I'm going to find out what is happening/status of their Registration filing with the SEC.
IE, Form S-1: Form S1 is the registration statement that the Securities and Exchange Commission (SEC) requires domestic issuers to file in order to publicly offer new securities. That is, issuers file S-1s for initial public offerings (IPOs) and follow-on offerings of new securities.
and
Form S-3: An S-3 filing is utilized when a company wishes to raise capital, usually as a secondary offering after an initial public offering has already occurred.
These were denied and rejected, and SEC refused to approve and accelerate 3 requests, one by AEGIS, and 2 by Steve Slilaty and then stated they will refuse to review the requests!
I have not seen any update on this..it puts this company in serious peril if they did not ever get this resolved. Don't believe this was ever resolved.
All reports can be find out here, I believe:
https://www.sec.gov/edgar/browse/?CIK=1402328&owner=exclude
and
https://www.sec.gov/Archives/edgar/data/1402328/000168316822003046/xslFormDX01/primary_doc.xml
https://www.sec.gov/Archives/edgar/data/1402328/000168316822003792/filename1.htm
https://www.sec.gov/Archives/edgar/data/1402328/000000000022005515/filename1.pdf
https://www.sec.gov/Archives/edgar/data/1402328/000168316822003385/sunshine_s3.htm
https://www.sec.gov/Archives/edgar/data/1402328/000168316822002425/filename1.htm
https://www.sec.gov/Archives/edgar/data/1402328/000000000022003720/filename1.pdf
End of the quarter/year approaching. Will be interesting to see what this companies financial health looks like.
Malek Chamoun has 7.4M shares. I did not see where he acquired the rest after the 3.7M acquisition deal for Nora. He by far is the largest of all holders.
10.3M shares are held by insiders. This is a bit lop sided in my opinion. 46% of the 22.5M O/S is held by insiders.
Transaction History
File Date Trade Date Form Insider Ticker Security Title Code 10b5-1 Direct Exercise Price Unit Price Units Changed Value Changed (1K) Remaining Options Remaining Shares
2022-12-02 2022-11-30 4 Sebaaly Camille SBFM Common Stock P - Purchase D 0.7635 30,000 23 174,465
2022-10-26 3 Chamoun Malek SBFM Common Stock, par value $0.001 per share D 3,700,000
2022-06-06 2022-06-03 4 Sebaaly Camille SBFM Common Stock P - Purchase D 1.2200 25,000 30 144,465
2022-02-22 2022-02-18 4 Slilaty Steve N. SBFM Series B Preferred Stock D - Sale to Issuer D 0.1000 -990,000 -99 10,000
2022-02-18 3 Keller Andrew Mark SBFM Common Stock D 0
2022-02-18 3 NATAN DAVID SBFM Common Stock D 0
2021-12-16 3 Kiderchah Rabi SBFM Common Stock D 325,000
2021-12-14 3 Kish James Daniel Held in the name of Reporting Person's Spouse SBFM Common Stock I 2,500
2021-12-14 3 Kish James Daniel SBFM Common Stock D 287,100
2021-12-09 3 TELSEY ANDREW I SBFM Common Stock D 3,000
2021-02-16 2021-01-06 4 Slilaty Steve N. SBFM Common Stock A - Award D 0.0010 20,000,000 20 23,343,461
2021-02-16 2021-01-06 4 MERZOUKI ABDERRAZZAK SBFM Common Stock A - Award D 0.0010 20,000,000 20 23,342,500
2021-02-16 2021-01-06 4 Sebaaly Camille SBFM Common Stock A - Award D 0.0010 20,000,000 20 23,893,086
2020-07-15 2019-12-31 4 Sebaaly Camille Held by TRT Pharma Inc. SBFM Common Stock A - Award I 0.0010 -323,673 -0 0
2020-07-15 2019-12-19 4 Sebaaly Camille SBFM Common Stock A - Award D 0.0010 1,300,000 1 3,893,086
2020-07-15 2019-10-20 4 Sebaaly Camille SBFM Common Stock A - Award D 0.0010 1,100,000 1 2,593,086
2020-07-15 2019-09-11 4 Sebaaly Camille SBFM Common Stock A - Award D 0.0010 550,000 1 1,493,086
2020-07-13 2019-12-19 4 MERZOUKI ABDERRAZZAK SBFM Common Stock A - Award D 0.0010 1,300,000 1 3,342,500
2020-07-13 2019-10-20 4 MERZOUKI ABDERRAZZAK SBFM Common Stock A - Award D 0.0010 1,100,000 1 2,042,500
2020-07-10 2019-12-31 4 Slilaty Steve N. Held by TRT Pharma Inc., an entity controlled by the Reporting Person. SBFM Common Stock J - Other I 0.0010 323,673 0 861,209
2020-07-10 2019-12-19 4 Slilaty Steve N. SBFM Common Stock A - Award D 0.0010 1,300,000 1 3,343,461
2020-07-10 2019-10-20 4 Slilaty Steve N. SBFM Common Stock A - Award D 0.0010 1,100,000 1 2,043,461
2020-06-25 2020-06-17 4 Slilaty Steve N. SBFM Series "B" Preferred Stock A - Award D 0.1000 500,000 50 1,000,000
2019-10-07 2018-06-20 4/A MERZOUKI ABDERRAZZAK SBFM Common Stock A - Award D 0.0010 27,000,000 27 79,000,000
2019-10-07 2018-08-27 4/A MERZOUKI ABDERRAZZAK SBFM Common Stock A - Award D 0.0010 38,000,000 38 117,000,000
2019-10-07 2019-09-02 4 MERZOUKI ABDERRAZZAK SBFM Common Stock A - Award D 0.0010 13,000,000 13 18,850,000
2019-10-04 3/A MERZOUKI ABDERRAZZAK Held by 91138107 Quebec, Inc. of which Reporting Person is a control person. SBFM Common Stock I 877,000
2019-10-04 3/A MERZOUKI ABDERRAZZAK Held by Axis Biosciences, Inc. of which Reporting Person is a control person. SBFM Common Stock I 590,000
2019-10-04 2018-04-22 4/A MERZOUKI ABDERRAZZAK SBFM Common Stock A - Award D 0.0010 12,000,000 12 12,000,000
2019-10-04 2016-12-06 4/A MERZOUKI ABDERRAZZAK SBFM Common Stock A - Award D 0.0010 28,000,000 28 38,000,000
2019-10-04 2017-07-20 4/A MERZOUKI ABDERRAZZAK SBFM Common Stock A - Award D 0.0010 14,000,000 14 52,000,000
2019-09-23 2019-09-02 4 Slilaty Steve N. SBFM Common Stock A - Award D 0.0010 13,000,000 13 18,869,219
2019-09-23 2019-09-11 4 Sebaaly Camille SBFM Common Stock A - Award D 0.0010 11,000,000 11 29,861,719
2019-09-23 2019-09-02 4 Sebaaly Camille SBFM Common Stock A - Award D 0.0010 13,000,000 13 18,861,719
2018-09-14 2018-08-27 4 Sebaaly Camille SBFM Common Stock A - Award D 0.0010 38,000,000 38 117,234,373
2018-09-14 2018-08-27 4 MERZOUKI ABDERRAZZAK SBFM Common Stock A - Award D 0.0010 38,000,000 38 118,467,000
2018-09-14 2018-08-27 4 Slilaty Steve N. SBFM Common Stock A - Award D 0.0010 38,000,000 38 117,384,373
2018-06-28 2018-06-20 4 MERZOUKI ABDERRAZZAK SBFM Common Stock A - Award D 0.0010 27,000,000 27 80,467,000
2018-06-28 2018-06-20 4 Slilaty Steve N. SBFM Common Stock A - Award D 0.0010 27,000,000 27 79,384,373
2018-06-28 2018-06-20 4 Sebaaly Camille SBFM Common Stock A - Award D 0.0010 27,000,000 27 79,234,373
2017-09-08 2017-07-20 4 MERZOUKI ABDERRAZZAK SFBM Common Stock A - Award D 0.0010 14,000,000 14 53,467,000
2017-09-08 2017-07-20 4 Sebaaly Camille SBFM Common Stock A - Award D 0.0010 14,000,000 14 52,234,373
2017-09-08 2017-07-20 4 Slilaty Steve N. SBFM Common Stock A - Award D 0.0010 14,000,000 14 52,384,373
2016-12-15 2016-12-06 4 Slilaty Steve N. SBFM Common Stock A - Award D 0.0010 26,000,000 26 38,384,373
2016-12-15 2016-12-06 4 Sebaaly Camille SBFM Common Stock A - Award D 0.0010 26,000,000 26 38,234,373
2016-12-15 2016-12-06 4 MERZOUKI ABDERRAZZAK SBFM Common Stock A - Award D 0.0010 26,000,000 26 39,467,000
2016-11-07 2016-10-10 4 Slilaty Steve N. Owned by Advanomics Corporation, an entity controlled by Reporting Person. SBFM Common Stock J - Other I -136,861,968 215,014,224
2016-11-07 2016-10-10 4 Sebaaly Camille Owned by 4019318 Canada Inc., an entity controlled by Reporting Person. SBFM Common Stock J - Other I 129,468,927 129,468,927
2016-11-07 2016-10-10 4 Advanomics Corp SBFM Common Stock J - Other D -136,861,968 215,014,224
2016-08-02 3 Advanomics Corp SBFM Common Stock D 703,752,384
2016-08-02 3 Advanomics Corp SBFM Common Stock D 703,752,384
2016-08-01 2016-07-08 4 Slilaty Steve N. Owned by Advanomics Corporation, an entity controlled by Reporting Person. SBFM Common Stock J - Other I 0.0026 321,305,416 835 351,876,192
2016-04-26 2016-04-22 4 Slilaty Steve N. SBFM Common Stock A - Award D 0.0070 12,000,000 84 12,384,373
2016-04-26 2016-04-12 4 Slilaty Steve N. Owned by Advanomics Corporation, an entity controlled by Reporting Person. SBFM Common Stock P - Purchase I 0.1976 253,082 50 30,570,776
2016-04-25 2016-04-22 4 Sebaaly Camille SBFM Common Stock A - Award D 0.0070 12,000,000 84 12,234,373
2016-04-25 2016-04-22 4 MERZOUKI ABDERRAZZAK SBFM Common Stock A - Award D 0.0070 12,000,000 84 13,467,000
2015-06-01 2015-05-27 4 Slilaty Steve N. SBFM Series "B" Preferred Stock P - Purchase D 0.1000 500,000 50 500,000
2015-03-20 3 MERZOUKI ABDERRAZZAK SBFM Common Stock D 2,934,000
2015-03-20 3 MERZOUKI ABDERRAZZAK SBFM Common Stock D 2,934,000
2015-01-22 2015-01-09 4 Slilaty Steve N. SBFM Common Stock J - Other D 0.0200 150,000 3 384,373
2015-01-22 2015-01-09 4 Slilaty Steve N. Owned by Advanomics Corporation, an entity controlled by Reporting Person. SBFM Common Stock J - Other I 0.0200 -1,200,000 -24 30,317,694
2012-10-05 2012-09-04 4/A Slilaty Steve N. Owned by Advanomics Corporation, an entity controlled by Reporting Person. SBFM Common Stock J - Other I 0.0500 -2,591,500 -130 31,517,694
2012-10-05 2011-12-21 4/A Slilaty Steve N. Owned by Advanomics Corporation, an entity controlled by Reporting Person. SBFM Series A Preferred Stock C - Conversion I 0.00 -17,000,000 0
2012-10-05 2011-12-21 4/A Slilaty Steve N. Owned by Advanomics Corporation, an entity controlled by Reporting Person. SBFM Common Stock C - Conversion I 17,000,000 34,109,194
2012-09-07 2012-09-04 4 Slilaty Steve N. Owned by Advanomics Corporation, an entity controlled by Reporting Person. SBFM Common Stock S - Sale I 0.0500 -2,591,500 -130 31,517,694
2012-09-07 2011-12-21 4 Slilaty Steve N. Owned by Advanomics Corporation, an entity controlled by Reporting Person. SBFM Series A Preferred Stock C - Conversion I 0.00 -17,000,000 0
2012-09-07 2011-12-21 4 Slilaty Steve N. Owned by Advanomics Corporation, an entity contolled by Reporting Person. SBFM Common Stock C - Conversion I 17,000,000 34,109,194
Whatever happened to hard work, stock options and awaredment of shares?
Guess open market is easier for Camille. He needs about 7M more to oust Mark and take the lead.
Garbage company/management ..even the boss don’t invest into his own company. He knows his science is BS..or better yet..just give himself and friends free shares in the future. Wont be a surprise their next offerings will be 40 cents a share.. plus another two free warrants again. Just in case they havent screwed their shareholders enough.. might as well screw us more for fun!!!..Worst management ever!!!
Secretary buying in open market but his boss not spending dime, why is that?
Maybe SBFM should do this, or have they.
https://dealstream.com/d/financial/public-shells/3gmsbr
Insider trading report:
Insider Name (profit %) Shares Owned Split Adjusted
Malek Chamoun 10% Owner - [10%] 7,400,000 7,400,000 (total shares as of today)
Camille Sebaaly CFO (Secretary) - [O] 9.04% 174,465 174,465 (same)
SBFM screwed all their shareholders.. the ones that held from otc to Nasdaq was wiped out…the new buyers in Nasdaq getting wiped out….shareholders whom bought sbfm when they first was a public traded company 10 yrs ago.. completely wiped out plus, Don’t forget..even if we lose all our money invested, shareholders still needed to pay for the multiple reverse splits fees along the way for holding this!!!
Very well said my friend !
Followers
|
756
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
113853
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
SUNSHINE BIOPHARMA INC
ANTI CANCER DRUGS
ANTI CORONA VIRUS RESEARCH
SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 - 5800 f
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |